Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye cancer survivors: does treatment choice impact Long-Term happiness?

NCT ID NCT03662776

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This study looks at children and teens who survived retinoblastoma in one eye. Researchers want to see if those who had chemotherapy injected into the eye artery have a different quality of life than those who had the eye removed. Participants and their parents will fill out surveys about emotional and behavioral health. The goal is to learn which treatment may lead to better long-term well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose treatments that better preserve quality of life for children with retinoblastoma.
What could go wrong
This is an observational study, not a treatment trial. It only looks at past treatments and cannot prove cause and effect. Results may not apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2018

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible survivors of unilateral retinoblastoma will be identified via the MSK and TCH databases and offered participation in the study.

Ages

8 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to speak and understand English or Spanish * Diagnosis of unilateral retinoblastoma at any age, confirmed by the enrolling institution * Treatment of retinoblastoma between 2006 or later * Patients must between the age of 8-17 years old * At least 1 year since completion of all cancer-directed therapy * Treatment with enucleation of the affected eye or intra-arterial chemotherapy Parent of patient: * Ability to speak and understand English or Spanish * Ability to confirm that he or she is the parent of a child treated for unilateral retinoblastoma who meets the eligibility criteria listed above * Ability to provide informed consent Exclusion Criteria: * Patients, or parents of patients, treated with both enucleation and intra-arterial chemotherapy are not eligible

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Survivors of unilateral retinoblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychological Well-Being unilateral retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Survivors of unilateral retinoblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Texas Children's Hospital (Data Collection)

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.